If new highs emerge, there has been no change in the game. Robots are still ruled by the old boss an...
Will IBM earnings be good enough to fuel the rally?
10/15/2009 11:16 pm EST
Sales fell 6.9% from the third quarter of 2008 to $23.6 billion. But that still beat Wall Street projections for sales of $23.4 billion.
Earnings for the third quarter climbed by 14% from the third quarter of 2008 to $2.40 a share. That was a penny ahead of Wall Street expectations.
And IBM raised guidance for the full year to at least $9.85 a share. Analysts had been calling for $9.78 a share.
And still the stock fell. Why? I"ve heard two explanations.
I think the drop is nothing but normal sell-on-the news profit taking. Shares of IBM had been up 7% this month. With earnings news behind them, some momentum traders I'm sure decided to sell.
If that's the case, then today's sell off in IBM isn't a sign of any real damage to the technology sector, which has been leading this rally recently. The results won't provide more fuel for the rally, it's true, but will leave the sector stuck in neutral waiting for reports from Texas Instruments (TXN) and Microsoft (MSFT) next week.
But I've heard a darker explanation. IBM announced that new contract signings dropped in the quarter. That could be a sign that IBM customers--and perhaps technology customers as a whole--aren't ready to step up with new orders quite yet.
Signed service contracts, for example, dropped 7% in the quarter.
Friday isn't likely to give investors a definite read on market reaction. After a strong move upward like we had in the first half of the week, stocks frequently take a hit on profit taking on Friday. No one wants to risk the week's gains over the weekend when markets are closed and traders can't react to news.
Next week, though, is likely to tell the tale.
Related Articles on STOCKS
Is the correction complete? Is it safe to start to seek bargains in the market? Don’t jump too...
There’s a 30% chance that the strong trend resumption will continue above January’s high...
We initiated coverage on drug contract research company Icon PLC (ICLR) in May 2016; in 17 months, t...